scholarly journals Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients

2020 ◽  
Author(s):  
Farzaneh Dehghani-Dehej ◽  
Zinat Hosseini ◽  
Poupak Mortazkar ◽  
Khadijeh Khanaliha ◽  
Maryam Esghaei ◽  
...  

Aim: HIV-infected patients risk coinfection with HBV and HCV. This study aimed to investigate molecular epidemiology of HBV and HCV coinfection in Iranian HIV-infected individuals. Materials & methods: In this cross-sectional study, serological markers of HBV and HCV infection (hepatitis B surface antigen [HBsAg], hepatitis B e-antigen [HBeAg], hepatitis B e-antibody [HBeAb] and hepatitis B core antibody [HBcAb]) and anti-HCV antibodies [anti-HCV Abs] were tested in 198 Iranian HIV-infected patients. From plasma, HBV viral load was determined using COBAS TaqMan 48, and HCV-RNA was detected by reverse transcriptase-nested PCR. Results: 85 out of 198 (42.9%) patients were anti-HCV Ab positive and 42/198 (21.2%) had detectable HCV-RNA. Eight (4.0%) had traceable HBV-DNA. All these patients were infected by HBV genotype D. 55 (27.8%) were HBcAb positive. Nine (4.4%) were HBsAg and anti-HCV Ab positive. Conclusion: None were HIV-RNA/HCV-RNA/HBV-DNA positive, 21.2% were HIV-RNA/HCV-RNA positive and 4.0% were HIV-RNA/HBV-DNA positive. Therefore, studies on diagnosing these infections in HIV-infected individuals may be valuable.

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Caroline Gahrton ◽  
Gabriel Westman ◽  
Karin Lindahl ◽  
Fredrik Öhrn ◽  
Olav Dalgard ◽  
...  

Abstract Background Identification and knowledge of settings with high prevalence of hepatitis C virus (HCV) infection is important when aiming for elimination of HCV. The primary aim of this study was to estimate the prevalence of viremic HCV infection among Swedish prisoners. Secondary aims were to estimate the prevalence of hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV), and the proportion who have received hepatitis B virus (HBV) vaccination. Methods A cross-sectional study of all incarcerated persons (n = 667) at all prisons (n = 9) in Stockholm County was conducted. All prisoners are routinely offered opt-in screening for HCV antibodies (anti-HCV), HCV RNA, HBsAg, anti-HBs, anti-HBc and HIV Ag/Ab at prison in Sweden. Data on the results of these tests and the number of received HBV vaccine doses were collected from the prison medical records. The parameters of HCV RNA, anti-HCV, and occurrence of testing for HCV were analysed in multiple logistic regression models in relation to age, sex and prison security class. Results The median age was 35 (IQR 26–44) years, and 93.4% were men. Seventy-one percent (n = 471) had been tested for anti-HCV, 70% (n = 465) for HBsAg and 71% (n = 471) for HIV. The prevalence of anti-HCV, HCV RNA, HBsAg and HIV Ag/Ab was 17.0, 11.5, 1.9, and 0.2%, respectively among tested persons. The proportion of prisoners who had received full HBV vaccination was 40.6% (n = 271) among all study subjects. Conclusions The prevalence of viremic HCV infection among Swedish prisoners in Stockholm County was 11.5%, which is high in comparison to the general population. Therefore, when aiming for the WHO goal of HCV elimination, prisons could suit as a platform for identification and treatment of HCV infection. There is a need to increase testing for blood-borne viruses and to improve vaccination coverage against HBV in Swedish prisons.


2020 ◽  
Vol 7 ◽  
pp. 204993612098212
Author(s):  
Rocío González ◽  
Luisa Barea ◽  
Ana Arruga ◽  
Alberto Richart ◽  
Vicente Soriano

Background: The risk of transfusion-transmitted viral infections is very low in developed countries. Recent massive migration flows from highly hepatitis B virus (HBV), hepatitis C virus (HCV) and/or HIV endemic regions to Europe may have changed this scenario. Methods: During 2017 and 2018, a total of 491,753 blood donations (291,762 donors) were evaluated at the Madrid Regional Transfusion Center. All were tested for hepatitis B surface antigen (HBsAg), anti-HCV and anti-HIV, as well as for HBV-DNA, HCV-RNA and HIV-RNA. Results: Overall, 35 donors were positive for HIV-RNA and 26 for HCV-RNA. HBV markers were found in 111 (0.022%) donors, split out into three categories: HBsAg+ ( n = 93; 0.019%), occult B infection (OBI) ( n = 17; 0.003%), and acute HBV window period ( n = 1; 0.0002%). All 17 OBI donors were positive for anti-HBc and confirmed as viremic in repeated testing. Viral load amounts were uniformly below 100 IU/mL. Ten OBI donors were repeated donors and look-back studies could be completed for eight of them. Fortunately, none of all prior recipients experienced transfusion transmitted hepatitis B. Compared with HBsAg+ donors, OBI donors were more frequently native Spaniards (76% versus 40%) and older (median age 52 versus 42 years old). Conclusion: Active HBV infection is currently found in 0.022% of blood donations (0.038% of donors) in Madrid. This rate is 3-fold greater than for HIV and/or HCV. On the other hand, HBsAg+ donors are 3-fold more frequent than OBI donors and more often immigrants than native Spaniards. No transfusion-transmitted HBV infections were identified during the study period, including retrospective checking of former recipients of OBI donors.


Author(s):  
Salah Tofik Jalal Balaky ◽  
Saeed Ghulam Hussain ◽  
Amer Ali Khaleel ◽  
Furat Tahseen Sabeer ◽  
Ahang Hasan Mawlood

Background & objectives: Introducing a nucleic acid test program is aimed to diagnose and reduces the risk of viral infection or transmission. DNA assay for HBV can detect infection in the windows period, chronic occult infection and can discriminate between active and inactive HBV infection. This cross-sectional study designed to diagnose, analyze HBV infection and to differentiate active from inactive infection based on viral DNA detection. Methods: Blood samples were collected from 256 patients previously diagnosed on the clinical ground as hepatitis B seropositive in Erbil Central Lab. The viral nucleic acid quantitative assessment was done for the collected samples using RT-PCR. Q-square was performed for statistical analysis. Results: Out of 256 collected blood samples 93 (36.3%) showed HBV-DNA positive titers above 50 IU/ml. Among positive subjects, 67 (72.04%) was categorized as inactive carriers (˂ 2000-20.000 IU/ml HBV-DNA titers). Conclusions: The data produced from this study confirmed the importance of the RT-PCR technique in sensitivity and reliability as a superior diagnostics tool specifically in differentiating active from inactive HBV carriers.


1969 ◽  
Vol 4 (1) ◽  
pp. 463-468
Author(s):  
JAVED IQBAL FAROOQI ◽  
RUKHSANAJAVED FAROOQI ◽  
RIAZMUHAMMAD ◽  
ZAFAR ALI ◽  
ABDURREHMAN ◽  
...  

Background: Both HBV super-infection in patients with chronic hepatitis C and HCV super-infectionin patients with chronic hepatitis B have been reported. In case of co-infection, hepatitis B and C interactwith each other and affect immune responses resulting in active HCV with inactive HBV, active HBVwith inactive HCV, both active and both inactive. The objective of our study was to find out andcorrelate the virological and clinical profile in our patients with chronic hepatitis B and C co-infection.Material and Methods: This observational, descriptive and cross-sectional study was conducted atMedical ‘A’ Ward, PGMI, LRH Peshawar and Author’s Private Hepatology Clinic, from July 2010 toJune 2014. All patients with HBsAg and Anti-HCV Reactive by ELISA for more than six months wereincluded in the study. Following investigations were carried out in these patients: Serum ALT, HBeAg,anti-HBe, HBV DNA PCR, HCV RNA PCR, and abdominal ultrasound. Data was entered and analyzedusing SPSS version 16.0.Results: A total of 130 patients were included in the analysis, out of which 81 (62.3%) were males.Mean age of patients was 40.52±14.27 years. Majority of patients belonged to age-group of 21-30 years.Mean serum ALT of patients was 83.69±60.48 U/L. Majority of patients belonged to ALT-Group of 41-80 U/L. Hepatitis C Virus was the dominant virus in 53% of patients. Chronic Hepatitis was thedominant clinical profile in 73% of patients.Conclusion: Hepatitis C Virus is the dominant virus in our patients with BC co-infection. There is nostatistically significant association between virological and clinical profile of these patients.Key Words: Hepatitis B Virus, Hepatitis C Virus, BC Co-infection, Chronic Hepatitis, Cirrhosis,Hepatocellular Carcinoma


2019 ◽  
Vol 113 (8) ◽  
pp. 437-445
Author(s):  
Anders Boyd ◽  
Menan Gerard Kouamé ◽  
Laura Houghtaling ◽  
Raoul Moh ◽  
Delphine Gabillard ◽  
...  

Abstract Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Côte d’Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as ‘infection’ (HBV DNA ≤10 000 copies/mL and normal alanine aminotransferase [ALT]) or ‘hepatitis’ (HBV DNA >10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19–31), 17 (40%) patients consistently had ‘infection’, 5 (12%) consistently had ‘hepatitis’ and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p<0.001), higher baseline ALT levels (p=0.02) and baseline hepatitis surface antigen >4.0 log10 IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation.


1970 ◽  
Vol 42 (3) ◽  
pp. 199-203
Author(s):  
ND Uleanya ◽  
EO Obidike

Background: Hepatitis B Virus (HBV) infection has reached pandemic proportions all over the world with areas of highest prevalence being the sub- Saharan Africa and Southeast Asia. Most deaths related to HBV are due to complications from chronic infection. Acquisition of infection at a younger age is the most important predictor of chronicity. Eradication of HBV is an important but difficult tasks facing public health. HB immunization is the single most important factor in hepatitis B control and was commenced in 2004 in Nigeria.Objectives: To determine the prevalence of Hepatitis B surface antigen (HBsAg) among children in the era of HB immunization, the risk factors of transmission and knowledge of mothers about their HB status.Methods: A cross sectional study carried out on one hundred and forty children aged 18 months to 15 years at the children outpatient clinic (CHOP) of the University of Nigeria Teaching Hospital, Ituku. Hepatitis B surface antigen (HBsAg) was determined using Determine Test Kits and a structured interviewer administered questionnaire administered.Results: Six were positive for HBsAg, giving a prevalence rate of 4.3%. HBsAg was least prevalent among children 1-5 years (2%). None of the children ≤ 5 years who received HB vaccination was positive for HBsAg though one child > 5 years who received the vaccine was positive. Sharing of toothbrushes among siblings was found to be a significantly associated risk factor. Only 6.4% of mothers knew their hepatitis B status.Conclusion: There is a gradual fall in the prevalence of HBsAg in our environment due to HB immunization. Sharing of toothbrushes may be a potent means of transmission of HBV infection.Keywords: HBV, Prevalence, Children, Transmission, HB immunization


Sign in / Sign up

Export Citation Format

Share Document